Nantahala Capital Management LLC Acquires New Holdings in VYNE Therapeutics Inc. $VYNE

Nantahala Capital Management LLC bought a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, Holdings Channel.com reports. The fund bought 2,000,000 shares of the company’s stock, valued at approximately $1,301,400,000. Nantahala Capital Management LLC owned about 2.99% of VYNE Therapeutics as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. T3 Companies LLC bought a new position in VYNE Therapeutics in the fourth quarter worth $548,000. ADAR1 Capital Management LLC boosted its stake in VYNE Therapeutics by 319.2% during the first quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock worth $636,000 after buying an additional 810,108 shares in the last quarter. GSA Capital Partners LLP bought a new stake in VYNE Therapeutics in the 2nd quarter valued at $47,000. Rangeley Capital LLC increased its holdings in VYNE Therapeutics by 18.1% in the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after buying an additional 18,064 shares during the period. Finally, KVP Capital Advisors LP bought a new stake in VYNE Therapeutics in the 4th quarter valued at $290,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Price Performance

Shares of VYNE opened at $28.32 on Friday. The company has a market capitalization of $18.98 million, a P/E ratio of -74.54 and a beta of 2.00. VYNE Therapeutics Inc. has a one year low of $14.03 and a one year high of $79.75. The business’s 50 day simple moving average is $31.74 and its 200-day simple moving average is $31.45.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million.

VYNE Therapeutics Announces Dividend

The firm also recently announced a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were paid a $19.00 dividend.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, VYNE Therapeutics has a consensus rating of “Sell”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.